ASRS 2019 Street Team: Peter K. Kaiser, MD

Article
Conferences|ASRS

Dr. Kaiser discusses how risuteganib fared in a phase II trial in patients with intermediate nonexudative AMD. 

Peter K. Kaiser, MD, shares the take-home message of his presentation, "Safety and Efficacy of Risuteganib in Intermediate Nonexudative Age-Related Macular Degeneration: First Time Results From a Phase 2 Study." Dr. Kaiser presented at the 2019 annual meeting of the American Society of Retina Specialists.

Recent Videos
Related Content
Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410

Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410

Article
Assessing the Evidence for Extending Treatment Intervals in nAMD & DME Management: Expert Insights into Innovative Approaches

Assessing the Evidence for Extending Treatment Intervals in nAMD & DME Management: Expert Insights into Innovative Approaches

Podcast
Richard Rosen, MD, honored with distinguished award from ASRS

Richard Rosen, MD, honored with distinguished award from ASRS

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
ASRS 2024: TEASE-3 study data shows progression stalled in early-stage Stargardt disease patients treated with gildeuretinol

ASRS 2024: TEASE-3 study data shows progression stalled in early-stage Stargardt disease patients treated with gildeuretinol

Article
ASRS 2024: Retina surgeon dexterity affected by external exposures

ASRS 2024: Retina surgeon dexterity affected by external exposures

Article
© 2024 MJH Life Sciences

All rights reserved.